A Randomised, Double-blind, Three-period Crossover Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With Type 1 Diabetes

Trial Profile

A Randomised, Double-blind, Three-period Crossover Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With Type 1 Diabetes

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Adverse reactions; First in man
  • Sponsors Adocia
  • Most Recent Events

    • 07 Jun 2017 New trial record
    • 01 Jun 2017 Results from this trial are expected in Q4 2017, according to an Adocia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top